Clinical Trials Logo
  1. Home
  2. Telangiectasis
  3. NCT00406380
  4. Details
NCT00406380 Clinical Trial

Effect of Avastin in Juxtafoveal Telangiectasias

Telangiectasis Clinical Trial

Official title:
Does Avastin Change Evolution in Juxtafoveal Telangiectasias?

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00406380
Other study ID # APEC-0024
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date September 2006
Est. completion date November 2006

Study information
Verified date May 2024
Source Asociación para Evitar la Ceguera en México
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

Description:

After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date November 2006
Est. primary completion date September 2006
Accepts healthy volunteers
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion - Patients with Idiopathic Juxtafoveal Retinal Telangiectasias Exclusion Criteria: - Diabetic Retinopathy and Diabetic Macular Edema - Hypertensive Retinopathy - Choroidal Neovascularization

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Bevacizumab

Procedure:
• Intravitreal injection of Bevacizumab

Locations
Country Name City State
Mexico Asociacion para Evitar la Ceguera en Mexico Mexico DF

Sponsors (1)
Lead Sponsor Collaborator
Asociación para Evitar la Ceguera en México

Country where clinical trial is conducted

Mexico, 

Outcome
Type Measure Description Time frame Safety issue
Primary Best corrected Visual Acuity
Primary Fluorescein Angiogram: Leakage
Primary Optical Coherence Tomography: Retinal thickness
See also
  Status Clinical Trial Phase
Completed NCT00005392 - Epidemiology of Venous Disease N/A
Completed NCT00005386 - Biobehavioral Determinants of Obesity in Black Women N/A
Completed NCT01205035 - High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia Phase 2
Completed NCT01362192 - Treatment of Lower Extremity Spider Veins With Excel V Phase 4
Completed NCT00725244 - Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias Phase 4
Withdrawn NCT02090517 - Laser Therapy Versus Electrosurgery For Nasal Telangiectasias N/A
Completed NCT02657252 - Polidocanol Versus Glucose Treatment of Telangiectasia Trial Phase 4
Completed NCT02104271 - Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. Phase 2
Completed NCT00451763 - Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia Phase 3
Completed NCT05860439 - Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias
Recruiting NCT00206921 - Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness N/A